Palantir UK executive Tom Watson reportedly told Labour MP Clive Lewis that some of his statements about the company’s public-sector work were “incorrect claims.” To support his argument, Watson cited NHS Federated Data Platform (FDP) figures. But reported trust-level results complicate those figures, and the UK statistics regulator says NHS England’s before-and-after comparisons cannot by themselves show that the platform caused the changes observed.
What did Tom Watson say to Clive Lewis?
The Register reported on 1 October 2026 that Tom Watson, Palantir’s newly appointed UK senior vice president, wrote to Labour MP Clive Lewis challenging statements Lewis had made about Palantir’s work in healthcare, policing and defence. According to the report, Watson drew on public statements, parliamentary material, interviews, opinion writing and social posts, and described Lewis’s claims as “incorrect claims.” The original letter was not independently available for review, so its contents and wording should be understood as reported by The Register, not as independently verified here.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Impact Data Books, Inc Round Count Book | $6.99 | Buy on Amazon |
| 2 |
|
Impact Data Books, Inc F-Class Book - Black - Standard - Regular 80 | $44.00 | Buy on Amazon |
The Register also reported that Lewis said the letter’s level of detail felt like “we’re watching you.” That is Lewis’s reported characterization of the letter; it does not establish that Watson made a threat.
What NHS FDP figures did Watson reportedly cite?
According to The Register, Watson said the NHS FDP was live at 142 trusts and that “137 are already reporting benefits.” The report also described figures associated with two FDP products. These measures have different populations and meanings, and should not be combined into a single measure of platform performance.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
| Reported figure | What it measures | Important qualification |
|---|---|---|
| 142 trusts live; 137 reporting benefits | Trust uptake and reported benefits, as cited by Watson | Reported by The Register; these figures do not, on their own, establish that FDP caused an improvement. |
| 111,589 additional patients undergoing procedures in operating theatres | An NHS England-reported benefit calculation associated with one inpatient coordination tool | The Register reported Foxglove’s analysis that 13 of the 41 trusts using that tool carried out fewer operations after its introduction. The aggregate calculation and those trust-level results are not equivalent measures. |
| 84 percent of the reported fall | The share attributed to Chelsea and Westminster Hospital NHS Foundation Trust of the reported outpatient waiting-list fall across 16 trusts using the relevant tool | As reported by The Register, this is a concentration within that reported fall, not an estimate of the tool’s causal effect across all trusts. |
The figures in this table are attributed to The Register’s reporting; they have not been independently verified against the underlying dataset or an NHS England benefits page. A reported count of patients or actions is also different from a calculated benefit based on comparing performance before and after a product’s introduction.
Can before-and-after figures prove the platform worked?
No. In a statement dated 22 July 2026, the Office for Statistics Regulation (OSR) explained that the relevant NHS England metrics are observational comparisons of performance before and after NHS FDP introduction. NHS England added this sentence to the relevant methods sections on 6 June 2026: “We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for.”
That caveat means the figures can describe changes observed after a product was introduced, but those comparisons alone cannot establish that FDP produced the changes. Other factors can affect procedure numbers and waiting-list performance. The Register noted staffing, case complexity and bed capacity as examples; those possibilities caution against attributing an aggregate change to the platform, but do not prove that FDP had no effect.
The distinction is between timing and causation: a metric may show that an outcome changed after implementation, while a causal estimate requires a method that can separate the product’s contribution from other influences. The OSR’s explanation and the caveat appear in its statement on NHS England’s FDP metrics.
How should the reported results be interpreted?
The 13-of-41 and 84-percent findings complicate broad claims that FDP tools improved performance uniformly. They do not, by themselves, settle the platform’s overall impact: the first concerns operations at a subset of trusts using one tool, and the second concerns the distribution of a reported outpatient waiting-list fall across trusts using another. Neither example is a complete controlled evaluation.
- Identify the speaker: Watson’s criticism of Lewis is a position reported by The Register, not proof that any particular statement by Lewis was wrong.
- Check the outcome and denominator: Trust counts, patient counts, operations and waiting-list changes measure different things. Keep each figure attached to its stated product, population and comparison.
- Separate reported activity from estimated benefit: A count of actions taken through an FDP product is not the same as a benefit calculated from before-and-after performance.
- Look for causal evidence: Ask whether other variables were controlled and whether results were compared with a suitable control group.
- Check whether an evaluation is complete: A planned independent study is not a completed finding.
What evaluation has the regulator documented?
The OSR welcomed NHS England’s commitments to label before-and-after metrics clearly, explain their limits in public communications, clarify methodological changes, publish trust-level information on benefits and consider comparisons with controls. It also said NHS England had commissioned Imperial College to conduct an independent academic evaluation, prioritising the Inpatients and OPTICA products.
The OSR statement records those commitments and the evaluation plan; it does not provide completed evaluation findings. Until such findings are available, the reported figures can inform discussion of uptake and observed changes, but they do not resolve whether FDP caused the claimed benefits.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
